trending Market Intelligence /marketintelligence/en/news-insights/trending/u-A_gangaT2O4f28LUAueA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Novartis sets completion date for Alcon spinoff

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Novartis sets completion date for Alcon spinoff

Novartis AG said the spinoff of its eye care business Alcon Inc. will be completed April 9.

The Swiss drugmaker will distribute 1 new Alcon share or American depositary receipt as a dividend-in-kind for every 5 Novartis shares or ADRs held.

Alcon's shares will trade on the SIX Swiss Exchange and on the New York Stock Exchange under the ALC symbol beginning April 9.

Alcon, which has secured $3.5 billion debt financing from a group of banks, was assigned Baa2 and BBB credit ratings by Moody's and S&P Global Ratings, respectively. The outlook is stable.

Bank of America Merrill Lynch and UBS AG are advising Novartis on the transaction.

This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings. Descriptions in this news article were not prepared by S&P Global Ratings.